Effect of Fiber on Glycemic Index (Fiber2)

Verifying Fibers Meet Regulatory Definitions for Nutrition Facts Labeling: A Randomized, Controlled Trial Evaluating Polydextrose

Primary objective is to investigate the effect of polydextrose on postprandial glucose concentrations in healthy adults when added to a food product.

Secondary objective is to assess gastrointestinal tolerance and acute bowel changes.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Dietary supplement: 8 g Polydextrose; Dietary supplement: 12 g Polydextrose; Dietary supplement: 16 g Polydextrose; Dietary supplement: Placebo

Detailed Description

This study is a randomized, 4-arm, single-blinded, controlled, cross-over trial design focused on determining the health benefits associated with Polydextrose intake.

A planned sample size of 40 will be enrolled into the study. This study will require one initial screening visit and 4 weekly study visits. This study will take approximately 4 weeks per subject to complete.

The initial screening visit will provide subject with the informed consent document and determine subject eligibility through anthropometric measurements, vital signs, fasting blood glucose test (finger prick), and completion of a survey relate to general eating, health, and exercise habits.

If willing and eligible to participate, subjects will be invited to participate in the study for 4 study days. Subjects will be instructed to maintain their usual diet pattern and physical activity throughout study duration. A dinner meal will be provided the day before the study visit to control the second meal effect from the food and beverage intake of the night before the study visit.

Subject will arrive at the center in a fasted state for at least 10 hours, well hydrated and rested. Each study visit will require blood draws throughout the visit. After evaluation of subject's health status (via anthropometric, vital sign and blood glucose measurements and in-person interview), a Licensed health Care Professional will place a catheter in subject's arm for the purpose of multiple blood sample collections and take the initial blood draw in the fasting state. Subjects will be randomized to receive a placebo or treatment beverage based on randomized treatment sequences for 4 study visits. The sequences of receiving the beverage treatments at each visit will be randomly assigned to one of sequences.

Each study visit will involve with blood samples collection at time points 0 (fasting), 0.5, 1, 2, 3 hour (h) for assessment of change in plasma glucose and insulin concentrations.

• Study Type: Interventional
• Enrollment (Actual): 40
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Illinois
    • Chicago, Illinois, United States, 60616
      • Clinical Nutrition Research Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 55 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subject is male or female aged between 20 and 55 years of age
• Subject has BMI between 20.0 and 32.0 kg/m2 at screening visit
• Fasting blood sugar less than 126 mg/dL
• Subject is willing to maintain a stable body weight and to follow his/her regular diet and physical activity patterns throughout the study period.
• Subject is willing to refrain from vigorous physical activity and consumption of alcoholic and/or caffeinated beverages 24 h prior to each test day
• Subject does not smoke or has abstained from smoking for at least 2 years
• No clinical evidence of cardiovascular, metabolic, respiratory, renal, gastrointestinal or hepatic disease
• Not taking any medications or dietary supplements that would interfere with outcomes of the study.
• Subject typically consumes a low fiber diet that correlates with the average fiber intake of typical western diet.

Exclusion Criteria:

• Subject currently smokes or has smoked within the past 2 years
• Men and women with known or suspected food intolerance, allergies or hypersensitivity to the study materials or closely related compounds
• Men and women known to have/diagnosed with diabetes mellitus
• Men and women with a fasting blood glucose concentration ≥126 mg/dL
• Average blood pressure > 140 mmHg/90 mmHg during screening visit
• Men and women with documented vascular disease, e.g., heart failure, myocardial infarction, stroke, angina, related surgeries
• Men and women with cancer other than non-melanoma skin cancer in previous 5 years
• Men and women who are taking medication or dietary supplements that may interfere with the outcomes of the study. Subjects may choose to go off dietary supplements (requires 30 days washout)
• Men and women who have donated blood within 3 months of the screening visit and blood donors/participants for whom participation in this study will result in having donated more than 1500 milliliters of blood in the previous 12 months
• Substance (alcohol or drug) abuse within the last 2 years
• Excessive coffee and tea consumption (> 4 cups/day)
• Unstable weight: gained or lost weight +/- 5 lbs in previous 3 months
• Women who are known to be pregnant or who are intending to become pregnant over the course of the study and women who are lactating.
• Men and women whom investigator is uncertain about subject's capability or willingness to comply with protocol requirements
• Special or atypical diet - eg. vegan, gluten free, excessively high or low energy/fiber
• Women who are taking unstable dose and brand of hormonal contraceptives and/or stable dose and brand less than 6 months.
• Men and women who do excessive exercise regularly or athlete

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Single

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Active Treatment 1; 8g Polydextrose	Dietary supplement: 8 g Polydextrose; 8g of Polydextrose
Experimental: Active Treatment 2; 12 g Polydextrose	Dietary supplement: 12 g Polydextrose; 12 g of Polydextrose
Experimental: Active Treatment 3; 16 g Polydextrose	Dietary supplement: 16 g Polydextrose; 16 g of Polydextrose
Placebo Comparator: Placebo; 0 g Polydextrose	Dietary supplement: Placebo; 0 g of Polydextrose

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in plasma glucose concentration over a 3 hour Oral Glucose Tolerance Test (OGTT) after administration of polydextrose (8 g, 12g, 16 g) compared to 0 mg placebo	3-hour Acute Postprandial plasma glucose Responses	3 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in gastrointestinal tolerance using the questionnaire in 3 days following treatment administrations.	3 days after administration of each treatment	3 days
Changes in bowel movement using the questionnaire in 3 days following treatment administrations.	3 days after administration of each treatment	3 days

Collaborators and Investigators

• Sponsor: Clinical Nutrition Research Center, Illinois Institute of Technology
• Investigators: Principal Investigator: Britt Britt Burton-Freeman, Ph.D, Illinois Institute of Technology

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2015
• Primary Completion (Actual): February 22, 2017
• Study Completion (Actual): December 19, 2018

Study Registration Dates

• First Submitted: November 20, 2015
• First Submitted That Met QC Criteria: November 25, 2015
• First Posted (Estimate): November 26, 2015

Study Record Updates

• Last Update Posted (Actual): January 27, 2021
• Last Update Submitted That Met QC Criteria: January 25, 2021
• Last Verified: January 1, 2021

More Information

Terms related to this study

• Keywords: Fiber; Glycemic Index; Polydextrose
• Other Study ID Numbers: IRB2015-104